Page last updated: 2024-12-05

2,4-dinitroaniline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4-dinitroaniline : A nitroaniline consisting of an aniline core having two nitro substituents located at the 2- and 4-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7321
CHEMBL ID354318
CHEBI ID34242
SCHEMBL ID33520
SCHEMBL ID18218196
MeSH IDM0056837

Synonyms (66)

Synonym
BIDD:ER0695
(2,4-dinitrophenyl)-amine
benzenamine, 2,4-dinitro-
aniline, 2,4-dinitro-
nsc8731
wln: wnr bz enw
97-02-9
1-amino-2,4-dinitrobenzene
nsc-8731
2,4-dinitroaniline
2,4-dinitroanilin
2,4-dinitroanilina
NCGC00091599-01
ai3-02920
nsc 8731
brn 0982999
2,4-dinitrobenzenamine
2,4-dinitroanilin [german]
2,4-dinitrophenylamine
2,4-dinitroanilina [italian]
hsdb 1142
ccris 2872
einecs 202-553-5
2,4-dinitraniline
GHL.PD_MITSCHER_LEG0.930
inchi=1/c6h5n3o4/c7-5-2-1-4(8(10)11)3-6(5)9(12)13/h1-3h,7h
2,4-dinitroaniline, 98%
STK260865
AC-11794
D0814
D90100
chebi:34242 ,
2,4-dinitro-phenylamine
CHEMBL354318
D2703
AKOS000119930
A845675
NCGC00091599-02
2,4-nitroaniline
2,4-dinitrobenzeneamine
2,4-dinitroaminobenzene
4-12-00-01689 (beilstein handbook reference)
unii-5bi780r6w6
5bi780r6w6 ,
dtxcid501823
dtxsid1021823 ,
NCGC00257680-01
cas-97-02-9
tox21_200126
BBL013156
FT-0610198
AE-641/01959064
2,4-dinitrobenzamine
2,4-dinitroaniline [mi]
SCHEMBL33520
SCHEMBL18218196
2,4-dinitro-aniline
W-100122
mfcd00007151
F0001-2303
2,4-dinitroaniline, analytical standard
(2,4-dinitrophenyl)amine
VS-03692
Q18785054
EN300-19491
2,4-dinitroaniline 1000 microg/ml in methanol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nitroanilineA substituted aniline that carries one or more nitro groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency50.11870.004023.8416100.0000AID485290
pregnane X receptorRattus norvegicus (Norway rat)Potency50.11870.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency47.32580.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency2.81900.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency39.41780.000221.22318,912.5098AID1259243; AID1259247; AID588516; AID743036; AID743063
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency37.60720.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency47.32580.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.10000.000214.376460.0339AID588532
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency29.86060.001530.607315,848.9004AID1224848; AID1224849
aryl hydrocarbon receptorHomo sapiens (human)Potency37.26960.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency29.86060.001723.839378.1014AID743083
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency44.29490.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency42.18180.000627.21521,122.0200AID651741; AID743202; AID743219
Nuclear receptor ROR-gammaHomo sapiens (human)Potency0.94390.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID200690Mutagenic activity in an Ames test on Salmonella Typhimurium TA98; Activity is log of revertants/nmol1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID23442Partition coefficient (logP)1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (24.00)18.7374
1990's2 (8.00)18.2507
2000's6 (24.00)29.6817
2010's9 (36.00)24.3611
2020's2 (8.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.50 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index47.76 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (96.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]